Introduction: Mantle cell lymphoma (MCL) responds well to initial therapy but most patients relapse and then respond only briefly to salvage therapy. Nevertheless, the median overall survival of MCL patients has dramatically improved from 30 months in the late 1970s to > 5 years at present. ...
Mantle cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells localized in primary follicles or in the mantle region of secondary follicles. MCL represents 2-10% of all non-Hodgkin lymphomas. Clinical presentation The male-to-female ratio in ...
This marks the only CAR T-cell therapy approved by the FDA for 4 subtypes of non-Hodgkin lymphoma.
Mantle cell lymphoma is a relatively new recognized hematological malignant disease, comprising of 2.5–6% non-Hodgkin’s lymphomas. The complexity of its clinical presentations (nodular pattern, diffuse pattern, and blastoid variant), variety in disease progression, and treatment response, make this ...
Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin lymphoma (NHL) of mature B-cells characterized by translocation, which is typically due to excess expression of Cyclin D1. Although with the progress in our knowledge of the causes for MCL and available treatments for MCL, this cancer ...
Mantle cell lymphoma (MCL) is a rare type ofnon-Hodgkin’s lymphoma (NHL)that arises in theB-lymphocytes, a type of white blood cell that helps fight infection. MCL usually affects lymph nodes and can also involve other organs. Most people with MCL have an aggressive form of the disease...
Mantle cell lymphoma (MCL) is a rare, B cell non-Hodgkin’s lymphoma with highly heterogeneous clinical presentation and aggressiveness. First-line treatment consists of intensive chemotherapy with autologous stem cell transplant for the fit, transplant
Mantle cell lymphoma (MCL) is an aggressive, rare form of non-Hodgkin lymphoma (NHL) that originates in the“mantle zone” of the lymph nodes and is most commonly found in the lymph nodes, bone marrow and spleen. MCL originates from white blood cells and accounts for about 5% of lympho...
Mantle cell lymphoma (MCL) is an aggressive disease with frequent relapse. Targeted therapies against B-cell receptor (BCR) molecules have demonstrated improved outcomes in relapsed cases. However, clinical responses are slow and selective, with failure to attain complete remission in a significant ...
However, MCL is typically an aggressive lymphoma characterized by rapid progression and high relapse rates even with multiagent therapy and is generally is considered incurable, except potentially for those eligible for autologous stem cell transplantation (ASCT) [5–9]. As such, initial decisions ...